MiRNA-based therapy for Lipid metabolism disorders: Bone morphogenetic protein 2 (BMP2) inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene miRNA-181a, 15/April/2015, 11.08 am

Molecular therapy for Human Cancer: FOXP3 suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) via up regulation of its target gene, 15/April/2015, 10.23 am
April 15, 2015
MiRNA-based Lifespan extension therapy: MiRNA-31 prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 15/April/2014, 11.14 am
April 15, 2015
Show all

A study from the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science & Technology of China, Hefei, Anhui 230027, China; Scientific and Educational Department, The second hospital of Anhui Medical University, Hefei, Anhui. 230061, China shows that “MiR-181a regulates lipid metabolism via IDH1.” This study was published in the 5 March  2015 issue of the Journal “Scientific Reports” by Prof Wu, Chu B, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Lipid metabolism disorders:  Bone morphogenetic protein 2 (BMP2) inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene miRNA-181a

Significance:   Given that: (1) more than two billion adults are overweight globally; (2) 64% of US population is Overweight; and (3) the risk of death raises by 20-40% among overweight people, there is an urgent need to find an effective therapy for treating disorders associated with overweight.

This study suggests, for the first time, that BMP2, by increasing the expression of its target gene miRNA-181a, it may inhibit the expression of IDH1 (Isocitrate dehydrogenase), a component of TCA cycle. Thereby, it may decrease and increase the expression of genes that promote lipid biosynthesis and β-oxidation, respectively. This, in turn, results in inhibition of lipid accumulation.  Thus, pharmacological formulations encompassing “BMP2 activators or small molecule compounds that increase the expression of both p-BMP2 and miRNA-181a” may be used (1) to lower body weight; and (2) in the management of obesity disorders.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, MiRNA-based therapy for Lipid metabolism disorders: Bone morphogenetic protein 2 (BMP2) inhibits the expression of IDH1 and lipid accumulation via up regulation of its target gene miRNA-181a, 15/April/2015, 11.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.